Disease Domain | Count |
---|---|
Nervous System Diseases | 1 |
Hemic and Lymphatic Diseases | 1 |
Neoplasms | 1 |
Infectious Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Target |
Mechanism ECE inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism Nrf2 stimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date03 Jun 2024 |
Sponsor / Collaborator |
Start Date19 Mar 2024 |
Sponsor / Collaborator |
Start Date20 Nov 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Methoxy-Apo-Enterobactin ( ECE ) | Candidiasis More | Preclinical |
Sinapic Acid ( Nrf2 ) | Cardiotoxicity drug-induced More | Preclinical |
Diallyl Disulfide | Leukemia More | Preclinical |
JY-0691 | Atherosclerosis More | Pending |